8 Results for "

NCI-N87 tumor cells

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "NCI-N87 tumor cells" in MCE Product Catalog:

Cat. No.: HY-P991526
CAS No.: 2933295-42-0
Target:  

CD3

Research Areas:  

Cancer

M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and CD3 on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .
loading...
    loading...
Cat. No.: HY-172970
CAS No.: 3093763-71-1
Research Areas:  

Cancer

HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .
loading...
    loading...
Cat. No.: HY-W1117786
CAS No.: 2241015-68-7
Target:  

ADC Payloads NAMPT

Research Areas:  

Cancer

Nampt-IN-10 (Compound 4) is an efficient inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). Nampt-IN-10 exhibits nanomolar-level inhibitory activity against cell lines such as MDA-MB453, NCI-N87, and NCI-H526. Nampt-IN-10 can be used as an ADC payload, and the ADC constructed with it as the core demonstrates significant anti-tumor activity .
loading...
    loading...
Cat. No.: HY-169323
CAS No.: 2921735-87-5
Synonyms: Mal-Exo-EEVC-MMAE
Research Areas:  

Cancer

APL-1091 (Mal-Exo-EEVC-MMAE) is an ADC payload-linker conjugate (Drug-Linker Conjugates for ADC). APL-1091 is formed by the conjugation of the Mal-Exo-EEVC (HY-169353) linker and MMAE (HY-15162), a microtubule inhibitor. APL-1091 resists aggregation at high drug-to-antibody ratio (DAR), exhibits excellent plasma stability, and reduces premature payload release. When conjugated with Trastuzumab (HY-P9907), APL-1091 displays anti-tumor activity in gastric cancer xenograft models. APL-1091 can be used for ADC synthesis and gastric cancer-related research .
loading...
    loading...
Cat. No.: HY-157085
CAS No.: 1184181-50-7
Target:  

HSP

Research Areas:  

Cancer

BX-2819 is a Hsp90 inhibitor with an IC50 value of 41 nM. BX-2819 inhibits the proliferation of cancer cells. BX-2819 can significantly inhibit the growth of NCI-N87 and HT-29 tumors in nude mice .
loading...
    loading...
Cat. No.: HY-163453
Target:  

EGFR

Research Areas:  

Cancer

HER2-IN-19 (Compound 10e) is a potent inhibitor of HER2 and EGFR with IC50 values of 0.87 respectively and 3.5 nM. HER2-IN-19 has potent inhibitory activity against tumor cells, IC50 NCI-N87 = 1.63 nM, IC50 BT474= 15.17 nM, IC50 BaF3-HER2YVMA = 1.49 nM .
loading...
    loading...
Cat. No.: HY-164346
CAS No.: 2879227-86-6
Amine-PEG8-Val-Cit-PAB-MMAE is a potent drug-linker conjugate for antibody-drug conjugates (ADCs).Amine-PEG8-Val-Cit-PAB-MMAE consists of the linker amine-PEG8-Vali-Cit-PAB and the payload MMAE (HY-15162), and can be used to synthesize ADCs. Amine-PEG8-Val-Cit-PAB-MMAE can be used for the research of gastric cancer, colon cancer, lung adenocarcinoma .
loading...
    loading...
Cat. No.: HY-183594
CAS No.: 3037373-65-9
Research Areas:  

Others

Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal is a linker-payload conjugate. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal contains the linker D-2,4-DHB-NH2-AA(bPEG8)-Mal (HY-183595) and the cytotoxic agent Exatecan (HY-13631), a potent DNA topoisomerase I inhibitor. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal can be utilized for the development of antibody-drug conjugates (ADCs) .
loading...
    loading...